411 related articles for article (PubMed ID: 29281848)
21. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
Yao Z; Jiang Y; Zhu X; Wu B; Bai S
Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
[TBL] [Abstract][Full Text] [Related]
22. Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study.
Häggström C; Garmo H; de Luna X; Van Hemelrijck M; Söderkvist K; Aljabery F; Ströck V; Hosseini A; Gårdmark T; Malmström PU; Jahnson S; Liedberg F; Holmberg L
Cancer Med; 2019 May; 8(5):2196-2204. PubMed ID: 30938068
[TBL] [Abstract][Full Text] [Related]
23. Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer.
Elshabrawy A; Wang H; Satsangi A; Wheeler K; Ramamurthy C; Pruthi D; Kaushik D; Liss M; Gelfond J; Fernandez R; Gore J; Svatek R; Mansour AM
Urol Oncol; 2021 Apr; 39(4):236.e9-236.e20. PubMed ID: 33423936
[TBL] [Abstract][Full Text] [Related]
24. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
25. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
[TBL] [Abstract][Full Text] [Related]
26. Radical Cystectomy
Haque W; Verma V; Butler EB; Teh BS
Anticancer Res; 2017 Oct; 37(10):5603-5608. PubMed ID: 28982876
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder.
Stensland KD; Zaid H; Broadwin M; Sorcini A; Canes D; Galsky M; Moinzadeh A
Eur Urol Oncol; 2020 Aug; 3(4):509-514. PubMed ID: 31411987
[TBL] [Abstract][Full Text] [Related]
28. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
[TBL] [Abstract][Full Text] [Related]
29. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
30. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
31. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
[TBL] [Abstract][Full Text] [Related]
32. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database.
Fairey AS; Jacobsen NE; Chetner MP; Mador DR; Metcalfe JB; Moore RB; Rourke KF; Todd GT; Venner PM; Voaklander DC; Estey EP
J Urol; 2009 Jul; 182(1):85-92; discussion 93. PubMed ID: 19447413
[TBL] [Abstract][Full Text] [Related]
33. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
34. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
35. National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.
Lin HY; Ye H; Kernen KM; Hafron JM; Krauss DJ
Cancer Med; 2018 Nov; 7(11):5370-5381. PubMed ID: 30306728
[TBL] [Abstract][Full Text] [Related]
36. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart RA; Birtle A; Maynard L; Beresford M; Blazeby J; Donovan J; Kelly JD; Kirkbank T; McLaren DB; Mead G; Moynihan C; Persad R; Scrase C; Lewis R; Hall E
BJU Int; 2017 Nov; 120(5):639-650. PubMed ID: 28453896
[TBL] [Abstract][Full Text] [Related]
37. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research.
Bekelman JE; Handorf EA; Guzzo T; Evan Pollack C; Christodouleas J; Resnick MJ; Swisher-McClure S; Vaughn D; Ten Have T; Polsky D; Mitra N
Value Health; 2013 Jun; 16(4):610-8. PubMed ID: 23796296
[TBL] [Abstract][Full Text] [Related]
38. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Vashistha V; Wang H; Mazzone A; Liss MA; Svatek RS; Schleicher M; Kaushik D
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1002-1020. PubMed ID: 28332983
[TBL] [Abstract][Full Text] [Related]
39. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.
Boorjian SA; Kim SP; Tollefson MK; Carrasco A; Cheville JC; Thompson RH; Thapa P; Frank I
J Urol; 2013 Jul; 190(1):55-60. PubMed ID: 23313198
[TBL] [Abstract][Full Text] [Related]
40. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
